PAXMAN receives a 10 MSEK line of credit as a financial buffer to enable increased expansion rate in the US
PAXMAN announces that the company has received a 10 MSEK line of credit to be used as a financial buffer for initial costs related to signed contracts in the United States, while at the same time being able to increase the rate of expansion on this important market. The line of credit is estimated to be more than sufficient until the PAXMAN group can deliver a positive cash flow."Our strong rate of expansion in the United States has exceeded even our own expectations since our FDA clearance in April last year. This is of course very encouraging, and the demand continues to grow amongst both